Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Likely To Take Holistic View Of AER Bill Compliance, Expert Says

This article was originally published in The Tan Sheet

Executive Summary

FDA will likely evaluate a company's compliance with adverse event reporting and record-keeping requirements on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center
Advertisement

Related Content

Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
AER bill signed into law

Topics

Advertisement
UsernamePublicRestriction

Register

PS100137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel